Summary & Overview
HCPCS Level II J9059: Bendamustine Hydrochloride Injection, 1 mg
HCPCS Level II code J9059 denotes the injectable antineoplastic agent bendamustine hydrochloride (Baxter), billed per 1 mg. This code captures the drug component of chemotherapy administration and is used across outpatient oncology infusion centers and clinic-based infusion suites nationwide. Accurate use of J9059 is important for drug utilization tracking, billing compliance, and payment reconciliation for cytotoxic chemotherapy.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the clinical context for bendamustine use, typical sites of service where J9059 applies, and the payer landscape relevant to reimbursement. The piece provides benchmarks and coding considerations commonly encountered in claims for single-agent bendamustine, notes on documentation elements typically required by major payers, and policy updates that affect drug billing and coverage determinations.
This summary is designed to help billing managers, oncology practice administrators, and revenue cycle teams understand where J9059 fits in the service line, what to expect from major national payers, and which operational details warrant attention when submitting claims for bendamustine injections.
Billing Code Overview
HCPCS Level II code J9059 represents injection, bendamustine hydrochloride (Baxter), 1 mg. The service is an injectable chemotherapy agent administered intravenously and is typically provided in oncology infusion settings, including hospital outpatient infusion centers and freestanding oncology clinics. Service type: chemotherapy administration (single-agent antineoplastic drug). Typical site of service: outpatient infusion center or oncology clinic.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with newly diagnosed chronic lymphocytic leukemia (CLL) or indolent non-Hodgkin lymphoma presents to an outpatient oncology infusion center for intravenous chemotherapy. The oncologist orders J9059 (bendamustine hydrochloride) dosed per body surface area. The patient registration team verifies demographics, insurance (e.g., Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, Medicare), and preauthorization if required. The nurse prepares bendamustine in the pharmacy under sterile conditions, confirms the dosing and the premix/compatible IV fluids, and performs pre-infusion assessments including vital signs and review of concurrent medications. The infusion is administered via peripheral IV or implanted port with appropriate monitoring for infusion reactions and hematologic toxicity. Post-infusion, nursing documents dose administered, lot numbers, and any immediate adverse events. Billing uses J9059 units corresponding to milligrams administered; applicable modifiers are appended when clinically indicated (for example, to denote unusual procedural services or multiple practitioners). Follow-up includes laboratory monitoring (CBC, CMP) and scheduling of subsequent cycles per the oncology protocol.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |